High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

Leukemia Research

Volumn 34, Issue 3, 2010, Pages 399-402

  Terpos, Evangelos ^a   Dimopoulos, Meletios A ^a   Shrivastava, Vikas ^b   Leitzel, Kim ^b   Christoulas, Dimitrios ^a   Migkou, Magdalini ^a   Gavriatopoulou, Maria ^a   Anargyrou, Konstantinos ^c   Hamer, Peter ^d   Kastritis, Efstathios ^a   Carney, Walter ^d   Lipton, Allan ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^d Oncogene Science   (United States)

Author keywords

Bone disease; Bone markers; Multiple myeloma; Survival; Tissue inhibitor of metalloproteinase 1 (TIMP 1)

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE DISEASE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL TIME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 77649187602     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.08.035     Document Type: Article

References (10)

1. Stetler-Stevenson W.G. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008, 1:re6.
2. Parmo-Cabañas M., Molina-Ortiz I., Matías-Román S., García-Bernal D., Carvajal-Vergara X., Valle I., Pandiella A., Arroyo A.G., Teixidó J. Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J Pathol 2006, 208:108-118.
3. Guedez L., Martinez A., Zhao S., Vivero A., Pittaluga S., Stetler-Stevenson M., Raffeld M., Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors. Blood 2005, 105:1660-1668.
4. Terpos E., Politou M., Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003, 123:758-769.
5. Terpos E., Szydlo R., Apperley J.F., Hatjiharissi E., Politou M., Meletis J., Viniou N., Yataganas X., Goldman J.M., Rahemtulla A. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003, 102:1064-1069.
6. Lipton A., Ali S.M., Leitzel K., Demers L., Evans D.B., Hamer P., Brown-Shimer S., Pierce K., Carney W. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 2007, 109:1933-1939.
7. Frederiksen C.B., Lomholt A.F., Lottenburger T., Davis G.J., Dowell B.L., Blankenstein M.A., Christensen I.J., Brunner N., Nielsen H.J. Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. Int J Biol Markers 2008, 23:42-47.
8. Terpos E., Mihou D., Szydlo R., Tsimirika K., Karkantaris C., Politou M., Voskaridou E., Rahemtulla A., Dimopoulos M.A., Zervas K. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005, 19:1969-1976.
9. Iniesta P., Morán A., De Juan C., Gómez A., Hernando F., García-Aranda C., Frías C., Díaz-López A., Rodríguez-Jiménez F.J., Balibrea J.L., Benito M. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep 2007, 17:217-223.
10. Yoshikawa T., Cho H., Tsuburaya A., Kobayashi O. Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer. Gastric Cancer 2009, 12:31-36.